Category: Replacement Heart Valves
New stented aortic bioprosthesis delivers outstanding implantability and performance.
Milan, Italy – Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today it has been granted CE mark certification for its innovative stented aortic bioprosthesis Crown PRT, now commercially available in Europe.
Italian device maker Sorin Group lands European regulatory approval for its next-generation Crown PRT replacement aortic heart valve.
Sorin Group (BIT:SRN) announced this week that it landed European CE Mark approval for its latest aortic heart valve, the Crown PRT.
European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely.
Boston Scientific launches European sales of its 25 mm Lotus aortic valve, adding to the 23 mm and 27 mm valves already on the market.
Boston Scientific (NYSE:BSX) is heading straight to market with its 25 mm Lotus transcatheter aortic valve after winning CE Mark approval this week, the company announced.
An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.
New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.
Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.
High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.
Israeli heart valve maker Mvalve reportedly pulls in a $15 million investment from Boston Scientific in a deal that includes a $200 million buyout option.